[The experimental study of specific inhibitor-CA-074Me of Cathepsin B suppressing retinal neovascularization].
OBJECTIVE
To observe the effect CA-074Me on the retinal neovascularization of C57BL/6J with retinal neovascularization, and to explore the new way of treatment for retinal neovascularization.


METHODS
It was a experimental study. Sixty-seven-days-old C57BL/6J mice were divided into four groups randomly including normal control group, blank control group, negative control group, experiment group. Blank control group, negative control group, experiment group were exposed to 75% oxygen to established a model of retinal neovascularization. Experiment group were injected with CA-074Me (5 mg x kg(-1) x d(-1)) by periocular injection one time every eye for 5 days after mice left oxygen box. Negative control group were received the same dose of DMSO at the same time. Normal control group and blank control group did not received any medicine. The Cathepsin B activity of the tissue of mice'eye were measured. The mean optical density of Cathepsin B of retina were measured by immunohistochemistry; the number of new vascular cell nuclei extending into the internal limiting membrane in cross-sections was measured. Retinal neovascularization were tested by the vascular pattern in adenosine diphosphate-ase (ADPase) stained retina flat-mounts.


RESULTS
CA-074Me reduced the Cathepsin B Activity, the number of new vascular cell nuclei extending into the internal limiting membrane, the non-vascular area of retina, and the ratio of the nonvascular area of retina and the whole retina area.


CONCLUSIONS
The specific inhibitor-CA-074Me of Cathepsin B can reduce the retinal neovascularization of C57BL/6J to some extent, may be a new treatment for retinal neovascularization in the future.
Zhou
Guo-Hong
GH
Center of Ophthalmology, Second Hospital of Peking University, Beijing 100044, China.
Yu
Wen-Zhen
WZ
Li
Xiao-Xin
XX
D000818:Animals; D002401:Cathepsin B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004151:Dipeptides / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D015861:Retinal Neovascularization / Q000378:metabolism* / Q000517:prevention & control*
D004151:Dipeptides; C068250:N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline; D002401:Cathepsin B